Comparison of prevalence of advanced fibrosis using LiverSTAT or FIB-4 combined with LSM/VCTE in a prospective chronic liver disease cohort (Mongolia) easlfibronostg on June 29, 2026 Category: Publications Tag: Diabetes, Hep B, Hep C, Identification, LiverSTAT, MASLD, Screening Post navigation Previous: Previous post: Combination of LIVERSTAT and Fibroscan-LSM outperforms FIB-4 and LSM for MASLD Advanced Fibrosis (F3F4) — multicenterNext: Next post: Association between Psoriasis severity and steatosis measured by LIVERFASt
